Jeff Johnson
Stock Analyst at Baird
(4.69)
# 102
Out of 4,829 analysts
139
Total ratings
60.42%
Success rate
31.15%
Average return
Main Sectors:
Stocks Rated by Jeff Johnson
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ZBH Zimmer Biomet Holdings | Maintains: Outperform | $130 → $115 | $95.21 | +20.79% | 14 | May 6, 2025 | |
| DXCM DexCom | Maintains: Outperform | $115 → $105 | $84.67 | +24.01% | 14 | May 2, 2025 | |
| TNDM Tandem Diabetes Care | Maintains: Neutral | $33 → $24 | $22.98 | +4.44% | 16 | May 1, 2025 | |
| COO The Cooper Companies | Maintains: Outperform | $117 → $107 | $82.26 | +30.08% | 16 | Mar 7, 2025 | |
| ALC Alcon | Maintains: Outperform | $104 → $108 | $95.75 | +12.79% | 9 | Feb 27, 2025 | |
| BBNX Beta Bionics | Initiates: Neutral | $20 | $13.95 | +43.37% | 1 | Feb 20, 2025 | |
| NVST Envista Holdings | Maintains: Neutral | $17 → $22 | $17.59 | +25.07% | 7 | Oct 31, 2024 | |
| SYK Stryker | Maintains: Outperform | $378 → $405 | $380.92 | +6.32% | 11 | Oct 30, 2024 | |
| ALGN Align Technology | Maintains: Outperform | $325 → $276 | $181.88 | +51.75% | 18 | Oct 24, 2024 | |
| HSIC Henry Schein | Maintains: Outperform | $92 → $82 | $68.64 | +19.46% | 9 | Aug 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $180 → $238 | $310.67 | -23.39% | 12 | Dec 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $70 | $33.05 | +111.80% | 2 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $53 → $61 | $14.45 | +322.15% | 4 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $78 → $67 | $15.82 | +323.51% | 6 | Feb 18, 2022 |
Zimmer Biomet Holdings
May 6, 2025
Maintains: Outperform
Price Target: $130 → $115
Current: $95.21
Upside: +20.79%
DexCom
May 2, 2025
Maintains: Outperform
Price Target: $115 → $105
Current: $84.67
Upside: +24.01%
Tandem Diabetes Care
May 1, 2025
Maintains: Neutral
Price Target: $33 → $24
Current: $22.98
Upside: +4.44%
The Cooper Companies
Mar 7, 2025
Maintains: Outperform
Price Target: $117 → $107
Current: $82.26
Upside: +30.08%
Alcon
Feb 27, 2025
Maintains: Outperform
Price Target: $104 → $108
Current: $95.75
Upside: +12.79%
Beta Bionics
Feb 20, 2025
Initiates: Neutral
Price Target: $20
Current: $13.95
Upside: +43.37%
Envista Holdings
Oct 31, 2024
Maintains: Neutral
Price Target: $17 → $22
Current: $17.59
Upside: +25.07%
Stryker
Oct 30, 2024
Maintains: Outperform
Price Target: $378 → $405
Current: $380.92
Upside: +6.32%
Align Technology
Oct 24, 2024
Maintains: Outperform
Price Target: $325 → $276
Current: $181.88
Upside: +51.75%
Henry Schein
Aug 7, 2024
Maintains: Outperform
Price Target: $92 → $82
Current: $68.64
Upside: +19.46%
Dec 21, 2023
Upgrades: Outperform
Price Target: $180 → $238
Current: $310.67
Upside: -23.39%
Aug 4, 2023
Maintains: Outperform
Price Target: $67 → $70
Current: $33.05
Upside: +111.80%
Jul 28, 2023
Maintains: Outperform
Price Target: $53 → $61
Current: $14.45
Upside: +322.15%
Feb 18, 2022
Maintains: Outperform
Price Target: $78 → $67
Current: $15.82
Upside: +323.51%